In the last few years, a great interest has emerged in investigating the pleiotropic effects of
Glucagon Like Peptide-1 Receptor Agonists (GLP-1RAs). While GLP-1RAs ability to lower …

The incidence of type 2 diabetes (T2D) has been increasing worldwide, and diabetic kidney
disease (DKD) remains one of the leading long-term complications of T2D. Several lines of …

Background Inflammation and hyperlipidaemia jointly contribute to atherothrombotic
disease. However, when people are treated with intensive statin therapy, the relative …

Abstract Type 2 Diabetes Mellitus (T2D) is a chronic disease with a pandemic incidence
whose pathogenesis has not yet been clarified. Raising evidence highlighted the role of …

Recent clinical trials in people with type 2 diabetes have demonstrated beneficial actions on
heart and kidney outcomes following treatment with GLP-1RAs. In part, these actions are …

In a phase 2 trial of once‐weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or
placebo, the dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide …

Objective. Rhizoma Coptidis is an herb that has been frequently used in many traditional
formulas for the treatment of diabetic mellitus (DM) over thousands of years. Berberine, the …

Background: Insulin secretory agents are commonly used to treat type 2 diabetes. However,
traditional insulin secretory agents such as sulfonylureas and glinides have side effects of …

Metabolic-dysfunction-associated steatotic liver disease (MASLD) is a chronic liver disease
that affects more than a quarter of the global population and whose prevalence is increasing …

Tirzepatide is a unimolecular co‐agonist of the glucagon‐like peptide‐1 (GLP‐1) and
glucose‐dependent insulinotropic polypeptide (GIP) receptors recently approved for the …